I am a Clinical Reader and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust. I graduated from University of Oxford in pre-clinical medicine in 1998 and from Imperial College London in Clinical Medicine in 2001. After seven years of training in medicine and oncology I took three years out of my clinical training to carry out a PhD in cancer immunotherapy from King’s College London. My PhD studies were focused on genetically modifying cells for cancer immune therapy with a technique called CAR T Cell therapy. After being awarded my PhD in 2011 I returned to complete my clinical training in medical oncology. I also continued my laboratory research with a Clinical Lecturership from the National Institute for Health Research (NIHR). In 2013 I was awarded a Medical Research Council Clinician Scientist Fellowship to pursue a career at the interface between clinical practice in medical oncology and novel immune therapy research and development. I have published over twenty five peer reviewed papers.
My research group at King's College London studies approachs to optimise personalised cell-based immune therapies for solid tumour oncology. Through vital collaborations with colleagues at King's and across the UK we are also studying the impact of immune therapies, called checkpoint inhibitor therapies, on human immune responses to help us better understand our remarkable immune systems and develop better ways of predicting, preventing and treating the immune related side effects of these crucial new drugs.
In my clinical practice I am a medical oncologist with a practice in malignant melanoma and Merkel Cell Carcinoma. I am a principal investigator in the Guy's Cancer Early Phase drug development team where I lead trials of new therapies or combinations in cancer patients. My particular focus is on cancer immune therapies, especially cellular therapies. I lead for skin cancer research at Guy’s and St Thomas’ NHS Foundation Trust, am our programme director for cell therapies and chair our biological safety committee.
I belive that quality cancer care is enhanced by bringing together skills in science and clinical practice. To do this well you need to be able to bring new treatments to patients and explain them well.
I have a young family who take up most of my spare time. And a garden I am more roud of than perhapse I should be!